$9.28
0.09[0.98%]
At close: May 21
$9.28
0[0.00%]
After Hours: 4:00PM EDT
TScan Therapeutics
(NASDAQ:TCRX)TScan Therapeutics Stock (NASDAQ:TCRX), Analyst Ratings, Price Targets, Predictions
TScan Therapeutics Inc has a consensus price target of $12.5, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from BTIG, HC Wainwright & Co., and Needham on May 16, 2024, May 14, 2024, and May 13, 2024. With an average price target of $12.67 between BTIG, HC Wainwright & Co., and Needham, there's an implied 36.49% upside for TScan Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BTIG
HC Wainwright & Co.
Needham
Wedbush
Barclays
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for TScan Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 29.31% | BTIG | Justin Zelin | → $12 | Initiates | → Buy | Get Alert |
| 05/14/2024 | Buy Now | 61.64% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 18.53% | Needham | Gil Blum | → $11 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 7.76% | Wedbush | David Nierengarten | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 03/07/2024 | Buy Now | -3.02% | Barclays | Peter Lawson | $7 → $9 | Maintains | Overweight | Get Alert |
| 03/07/2024 | Buy Now | 61.64% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 02/01/2024 | Buy Now | -3.02% | Wedbush | David Nierengarten | → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 08/14/2023 | Buy Now | 61.64% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | -13.79% | Wedbush | David Nierengarten | → $8 | Initiates | → Outperform | Get Alert |
| 05/18/2023 | Buy Now | 61.64% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 61.64% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/09/2023 | Buy Now | 61.64% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | → Buy | Get Alert |
| 05/10/2022 | Buy Now | 61.64% | HC Wainwright & Co. | Andrew Fein | $21 → $15 | Maintains | Buy | Get Alert |
| 12/16/2021 | Buy Now | 126.29% | HC Wainwright & Co. | Andrew Fein | — | Initiates | → Buy | Get Alert |
| 08/13/2021 | Buy Now | — | Cowen & Co. | Boris Peaker | — | Initiates | → Outperform | Get Alert |
| 08/10/2021 | Buy Now | 137.07% | Morgan Stanley | Vikram Purohit | — | Initiates | → Overweight | Get Alert |
| 08/10/2021 | Buy Now | 126.29% | Jefferies | Chris Howerton | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for TScan Therapeutics (TCRX)?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by BTIG on May 16, 2024. The analyst firm set a price target for $12.00 expecting TCRX to rise to within 12 months (a possible 29.31% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TScan Therapeutics (TCRX)?
The latest analyst rating for TScan Therapeutics (NASDAQ: TCRX) was provided by BTIG, and TScan Therapeutics initiated their buy rating.
When was the last upgrade for TScan Therapeutics (TCRX)?
There is no last upgrade for TScan Therapeutics.
When was the last downgrade for TScan Therapeutics (TCRX)?
There is no last downgrade for TScan Therapeutics.
When is the next analyst rating going to be posted or updated for TScan Therapeutics (TCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TScan Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TScan Therapeutics was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating TScan Therapeutics (TCRX) correct?
While ratings are subjective and will change, the latest TScan Therapeutics (TCRX) rating was a initiated with a price target of $0.00 to $12.00. The current price TScan Therapeutics (TCRX) is trading at is $9.28, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.